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Abstract
A high frequency of IgA1-positive tumour cells was found in tissue micro-arrays
of oesophagus, colon, testis, lung, breast, bladder and ovarian cancer. IgA1 was
observed in the cytoplasm and the plasma membrane. A correlation was found
between intra-tumour IgA1 and poor overall survival in a large cohort of bladder
cancer patients (n = 99, p = 0.011, log-rank test). The number of IgA1-positive
tumour cells was also found to be higher in female than male bladder cancer
patients. The presence of IgA1 was confirmed in formalin-fixed paraffin-embedded
ovarian carcinoma samples using LC-MS/MS analysis. Uptake of IgA1 was also
observed in breast cancer and melanoma cell lines when cultivated in the presence
of serum from healthy individuals, indicating a possible origin of the IgA1
antibodies in cancer cells.
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1. Introduction
There are reports in the literature of increased concentrations of the secretory
component of immunoglobulin A (IgA) and a higher expression of IgA and IgM in
serum from patients with cancer [1, 2]. The presence of IgA1 in preparations from
neoplasms of epithelial origin was first reported in 1996 by Streets et al. [3]. When
analysing Helix pomatia agglutinin-binding glycoproteins from primary breast
cancers, they found IgA1 to be a major component among the Tn antigen- (O-
linked serine/threonine-alpha GalNac) positive proteins. In a previous study we
confirmed the high frequency of IgA1 staining in breast cancer tissue sections,
where we found clearly IgA1-positive but heterogeneous intra-tumour staining [4].
Invasive parts of the tumours were found to be more intensively stained than the in
situ component, and both the cytoplasm and the plasma membrane were stained. In
this study we wanted to investigate if the expression of IgA1 was exclusive for
breast carcinoma or if IgA1 also were expressed in other forms of carcinomas. The
origin of tumour-associated immunoglobulins is not known, but there are several
kinds of receptors for IgA uptake [5], suggesting receptor-mediated uptake from
surrounding blood plasma as an alternative to when synthesized and released
antigens binds to IgA into a complex and then by endocytosis enters the cell [6]. In
this study, we investigated the frequency of tumour-associated IgA1 in a number of
different cancers, and investigated the relationship between IgA1 and clinical
outcome in a large cohort of bladder cancer patients.
2. Subjects and methods
2.1. Subjects
Tumours are from oesophagus (n = 12), colon (n = 48), testis (n = 57), lung
(n = 12) breast (n = 52), ovarian (n = 50) and bladder (n = 110). The present study
was approved by the Ethics Committee at Lund University (Ref. 445/2007) and
informed consent was obtained from all patients.
2.2. Tissue micro-array construction
All the tumours were histopathologically re-evaluated and classified according to
the WHO grading system of 2004 by a board-certified pathologist before tissue
micro-array (TMA) construction. Areas representative of the cancer were then
marked, and TMAs were constructed as described previously [7]. Briefly, two
tissue cores were taken from each tumour and mounted in a new recipient block
using a semi-automated arraying device (TMArrayer, Pathology Devices, Inc.,
Westminster, MD, USA).
Article No~e00143
2 http://dx.doi.org/10.1016/j.heliyon.2016.e00143
2405-8440/© 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2.3. Immunohistochemistry
For immunohistochemistry (IHC) analysis, 4-μm TMA sections were automatical-
ly pretreated using the PT Link system (DAKO, Glostrup, Copenhagen, Denmark),
and then stained in an Autostainer Plus (DAKO, Glostrup, Copenhagen, Denmark)
with the primary antibody M4D8 anti-human IgA1 (dilution 1:3000) obtained from
Margaret Goodall at The School of Immunity & Infection, Birmingham University
(UK). The specificity of the antibody has been demonstrated previously [8].
2.4. Bladder cancer patients
Consecutive patients diagnosed with urothelial bladder cancer at the Department of
Pathology, Skåne University Hospital, Malmö, from 1 October 2002 until 31
December 2003, for whom archival transurethral resection specimens of the
bladder could be retrieved were included in the cohort (n = 110). The cohort
included 80 men (72.7%) and 30 women (27.3%), and the median age was 72.9
years (range 39.3–89.9 years). Information on vital status was obtained from the
Swedish Cause of Death Register up to 31 December 2010. Follow-up started at
the date of diagnosis and ended at death, emigration or on 31 December 2010,
whichever was first. The median follow-up time was 5.92 years (range 0.03–8.21
y) for the whole cohort, and 7.71 years (range 7.04–8.21 y) for patients alive
(n = 48) on 31 December 2010. Forty-eight patients (43.6%) died within 5 years.
The T-stage distribution of the tumours was: 48 (43.6%) pTa, 24 (21.8%) pT1, 37
(33.8) pT2 and 1 (0.9%) pT3. Eighteen (16.4%) tumours were Grade I, 34 (30.9%)
Grade II and 58 (52.7%) Grade III. This cohort has also been described previously
[9, 10, 11]. Following antibody optimisation and staining, IgA1 expression could
be evaluated in 99 out of 110 tumours (90%). Those that could not be evaluated
were either the result of complete tissue loss during IHC preparation or an
insufficient quantity of tumour tissue during IHC preparation. The expression of
IgA1 was assessed as the staining of the cytoplasma and then categorized into five
groups: 0 (0%–1%), 1 (2%–25%), 2 (26%–50%), 3 (51%–75) and 4 (>75%). The
cytoplasmic staining intensity was also noted as 0 = negative, 1 = intermediate,
2 = moderate and 3 = strong intensity. A combined score was then obtained by
multiplying the staining scores of IgA1 by the staining intensity, resulting in
categories ranging from 0 to 12. For survival analysis, this variable was
dichotomized into low (categories 0–2) and high (categories 3–12) IgA1-
expressing groups.
2.5. Statistical analysis for bladder cancer
To test for correlations between IgA1 and clinical parameters, Spearman’s rank
correlation coefficient (rho, ρ) was used. Overall survival was investigated using
Kaplan-Meier analysis combined with the log-rank test to elucidate differences in
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outcome. Cox regression analysis was performed to estimate the relationship
between survival and IgA1 status, unadjusted and adjusted for age, grade and T-
stage. All statistical analyses were carried out using IBM SPSS Statistics version
23 (IBM Corporation, Armonk, NY, USA). All p-values were two-sided and
differences were considered significant when p < 0.05.
2.6. Tissue excision from ovarian cancer tumours and protein
digestion
Nine cores were excised from the formalin-fixed paraffin-embedded blocks from
nine patients with ovarian cancer, and transferred to Eppendorf tubes. The nine
samples were taken from sections with low (T4080, T22530 and T13975), medium
(T3260, T10387 and T12696) or high (T195, T15392 and T2852) expression of
IgA1 based on IHC. The cores were deparaffinised using 1 mL EnVisionTM FLEX
target retrieval solution (High pH) (Dako, Glostrup, Denmark) and heated for
10 min at 98 °C. Samples were centrifuged for 10 min at 14000 x g at 4 °C. The
paraffin, floating on the surface, was removed, and the retrieval solution was
aspirated. Another mL of fresh retrieval solution was added to the samples, which
were heated for another 10 min at 98 C followed by centrifugation for 10 min at
14000 x g at 4 °C. The retrieval solution was again aspirated. To these tissue
samples, 300 μL 6 M guanidine chloride in 50 mM ammonium bicarbonate was
then added. The samples were sonicated for 5 min with a Branson SLPe sonicator
(Branson Ultrasonics, Danbury, CT, USA) in continuous mode. The samples were
then centrifuged at 14000 x g for 10 min at room temperature. The supernatants
were transferred to new tubes and the pellets were discarded. The protein
concentration was measured using a Bicinchoninic acid protein assay according to
the manufacturer’s instructions (Micro BCA kit, Pierce, Thermo Scientific,
Rockford, IL, USA). The samples, 150 μg proteins, were reduced with
dithiothreitol and alkylated with iodoacetic acid before trypsination, as described
previously [12].
2.7. Label free quantification by LC-MS/MS analysis
Samples, 1 μg were analysed using LC-MS/MS in an Easy-nLC II system coupled
to a QExactive mass spectrometer (Thermo Scientific, San José, CA, USA). The
peptides were concentrated (on-line) by reverse-phase chromatography using a
20 mm x 0.75 mm, 3 μm C18 RP pre-column (Acclaim PepMap® 100, nanoViper),
and then separated using a 250 mm x 0.075 mm, C18, 2 μm, 100 Å column
(Acclaim PepMap® 100 RSLC, nanoViper) at a flow rate of 300 nL/min, both from
Thermo Scientific (San José, CA, USA).
Raw data files were analysed with Proteome Discoverer v 1.4 (Thermo Scientific).
Peptides were identified using SEQUEST HT against the UniProtKB human
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database integrated into Proteome Discoverer. Two unique peptides,
DASGVTFTWTPSSGK and TFTCTAAYPESK, were selected for IgA1. MS1
full scan filtering chromatogram-based quantification was performed in Skyline
version 3.1 (http://proteome.gs.washington.edu/software/skyline) [13]. Quantita-
tive analysis was based on extracted ion chromatograms (XICs) and resulting
precursor ion peak areas for each peptides M, M+1 and M+2, i.e. the first, second
and third isotopic envelope. The sample digests were then subjected to new
targeted scheduled LC-MS/MS runs with an isolation list of the precursors and
with a time window of 2 min. Data from the individual tumour lysates are
presented as mean of triplicates measurements +/− standard deviation.
2.8. Culturing and analysis of melanoma and breast cancer cells
The cell lines, T47D (breast cancer) and C8161 (melanoma) were cultured close to
confluency at 37 °C in an atmosphere of 5% CO2 in RPMI medium supplemented
with GlutaMAXTM, 10% foetal calf serum (FCS), penicillin (100 μg/mL) and
streptomycin (100 μg/mL). In half of the cultures the medium was changed to
RPMI 1640 medium supplemented with 75% pooled human serum from healthy
blood donors. These cells were cultured for 24 h. Cells were harvested by 5 min’
incubation with trypsin/EDTA at 37 °C. The cells were then washed three times
with PBS before fixation with 2% paraformaldehyde and permeabilized with 0.1%
saponin, 5% BSA in PBS. The cells were either stained with the primary antibody
anti-IgA1 (M4D8) or a negative control mouse IgG antibody (2 μg/mL) for 1 h,
followed by three washes with PBS. As secondary antibody, a FITC-labelled anti-
mouse Ig (F0261, Dako) diluted 1/500 was used. The cells were analysed for the
presence of IgA1 uptake using an ImageStream® Mark-II imaging flow cytometer
(Amnis, Seattle, WA, USA).
3. Results
3.1. Presence of IgA1 in different cancer tissues
Most of the tumour samples investigated, from all tumour types i.e., oesophagus,
ovarian, testis, bladder, lung, breast and colon cancer, stained positive for IgA1
(Table 1). IgA1 was frequently seen in both the cytoplasm and plasma membrane
of the cancer cells, as can be seen in Fig. 1.
3.2. Findings related to bladder cancer
A larger number of cases of bladder cancer (n = 99) were evaluated to investigate
the possible correlation between IgA1 score and patient outcome. A high
IgA1score (i.e. many and/or intensively stained IgA1-positive cells) was
significantly correlated with gender in that tumours from female patients were
more frequently IgA1-positive than tumours from male patients (Table 2). High
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tumour-specific IgA1 expression was also correlated with significantly poorer
overall survival (Fig. 2). When adjusting for patient age, and tumour grade and T-
stage in a multivariable Cox analysis, age remained the strongest parameter
Table 1. A summary of IgA1-positive and -negative cancer TMA samples in
seven common kinds of cancer.
Tumour n Positive Negative
Oesophagus 12 10 2
Ovarian 50 47 3
Testis 57 52 5
Bladder 99 61 38
Lung 12 12 0
Breast 52 46 6
Colon 48 38 10
[(Fig._1)TD$FIG]
Fig. 1. Images of tumour sections after immunohistochemical staining for IgA1 from1) oesophagus, 2)
ovarian, 3) testis, 4) bladder and 5) breast cancer tissue. Tissue sections are from individual patients
illustrating the differences in staining intensity.
Article No~e00143
6 http://dx.doi.org/10.1016/j.heliyon.2016.e00143
2405-8440/© 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
predicting overall survival, and the significance of IgA1 expression was lost
(Table 3).
3.3. Ovarian tumours
The relative amount of IgA1 in the nine samples of ovarian tumours was quantified
using two unique peptides, DASGVTFTWTPSSGK and TFTCTAAYPESK, from
the protein. Data from the individual tumour lysates are presented as the mean of
triplicate measurements ± standard deviation (Fig. 3). The IgA1 staining of the
same tumour is shown in Fig. 4.
3.4. Breast cancer and melanoma cells
Breast cancer and melanoma cells cultivated in FCS stained negative for IgA1
using flow cytometry. However, cells cultivated in human serum stained positive
Table 2. Expression of IgA1 expression in bladder cancer.
IgA1a
Factor N rho P value
Sexb 99 -0.296 0.003
Gradec 99 0.178 0.079
Staged 99 0.262 0.009
N = number of patients.
a Staining x intensity.
b Female vs. Male.
c I, II and III.
d pTa, pT1, pT2 and pT3.
[(Fig._2)TD$FIG]
Fig. 2. Kaplan-Meier plot of the overall survival in 99 patients with bladder cancer. A high IgA1 score
is associated with poorer overall survival (p = 0.011, log-rank test).
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Table 3. Uni- and multivariable Cox regression analysis of overall survival in the
bladder cancer cohort (N = 99).
Univariable Multivariable
Variable HR 95% CI p-value HR 95% CI p-value
Agea 1.08 1.05 to 1.10 <0.001 1.07 1.04 to 1.10 <0.001
Gradeb 3.70 2.13 to 6.44 <0.001 1.44 0.63 to 3.30 0.387
T-stage
pTa 1.00 1.00
pT1 4.12 2.09 to 8.11 <0.001 2.60 1.09 to 6.17 0.032
pT2 + 3 4.13 2.19 to 7.80 <0.001 2.24 0.85 to 5.90 0.104
IgA1c 1.99 1.16 to 3.43 0.013 1.79 0.99 to 3.24 0.056
HR = hazard ratio.
CI = confidence interval.
a Continuous.
b Grade I-II vs. III.
c IgA1 low vs. high.
[(Fig._3)TD$FIG]
Fig. 3. IgA1 expression levels of the two selected peptides in nine individual patient ovarian cancer
tissue samples using LC-MS/MS. The results are given as the mean and SD of triplicate measurements.
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for IgA1 when the cells had been fixated and permeabilized, clearly showing an
uptake of IgA1 (Fig. 5).
4. Discussion
The aim of the present study was to investigate the frequency of IgA1-positive
cells in tumours from different types of cancer. It is clear from the results that the
presence of IgA1 in cancer cells is a common phenomenon. In the seven types of
tumours investigated, over 80% of the tumour samples stained positive for IgA1.
The score for IgA1-positive cancer cells in patients with bladder cancer (n = 99)
was correlated with the tumour stage and overall survival, indicating a relation
between the presence of IgA1 in cancer cells and poor prognosis. Patients with
high IgA1-expressing tumours had a significantly lower overall survival than those
with low IgA1-expressing tumours. When adjusting for known prognostic factors
such as age, this association was lost.
The presence of IgA was confirmed in tissue sections from ovarian cancer;
however, the relative quantities determined with LC-MS/MS were not always
correlated with the corresponding IHC (Fig. 3 and Fig. 4). For example tumour
T2852 obtained the most intense IgA1 staining with IHC, but not the highest
relative quantity when analysed using LC-MS/MS. This could be explained by the
heterogeneity of staining seen in whole histological sections [14].
Neither the origin nor function of the immunoglobulins found in cancer cells is
known. Apart from possible immune responses to the tumour, uptake by a number
[(Fig._4)TD$FIG]
Fig. 4. Images of ovarian tumour sections after immunohistochemical staining for IgA1. Section with
low A) T4080, B) T22530, C) T13975, medium D) T3260 E) T10387, F) T12696 and high G) T195, H)
T15392 and I) T2852 expression of IgA1.
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[(Fig._5)TD$FIG]
Fig. 5. Image stream analysis of the presence of IgA1 in human cell lines T47D (breast cancer) and
C8161 (melanoma) cultured in human serum and in FCS. Fixed cells were permeabilized and stained
with anti IgA1 antibody and visualized with a secondary FITC-labelled anti-mouse Ig antibody. A) The
intensity of the IgA1 fluorescence signal plotted against the relative cell area of C8161 cells cultivated
in human serum or foetal calf serum. R2 indicates the gate with cells regarded as positively stained for
IgA1 uptake. Three representative individual B) C8161 cells C), and T47D cells after culture in human
serum showing strong (+++), weak (+) and no staining (−) for IgA1. Channel 1 (Ch01) bright field,
channel 2 (Ch02) FITC and IgA1 uptake, channel 6 (Ch06) represent side scatter.
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of receptors may be possible; Fc alphaRI (CD89), pIgR, Fc α/μR, asialo-
glycoprotein receptor and the transferrin receptor all with the capacity to transfer
IgA1 into the cell [5]. A specific immune response to tumours could result in the
uptake of immunoglobulins in a similar way to that observed in virus-infected cells
[6]. IgA, IgM and IgG can all enter into virus infected cells in vitro and via the high
affinity IgG receptor, TRIM21, the immunoglobulins can then bind and support
destruction of virus inside the cell [15]. It might be possible that anti-tumour
antibodies can act in a similar way through TRIM21 by destroying the antigen and
perhaps promoting tumour growth. When cultivating cell lines which were found
to be IgA1-negative in the presence of human serum, a portion of the cells showed
an uptake of IgA1 after 24 h, which demonstrates the capability of tumour cells to
internalize IgA1 from serum.
It has been suggested that the presence of immunoglobulins in tumour cells is due
to the fact that non-lymphoid cells, including cancer cells, express immunoglo-
bulins [16, 17, 18]. However, we were not able to confirm any production of
immunoglobulins by tumour cell lines in the present study or in our previous study
[4]. Neither could Babbage et al. [19] detect any IgA chain on protein level after
sorting EpCAM-positive epithelial cancer cells using FACS, although they did
detect Ig on the mRNA level.
In conclusion, IgA1 is present in tumour cells in a wide range of cancers, and the
presence of IgA1 in tumour cells is correlated with poor prognosis in bladder
cancer. However, the origin and function of immunoglobulins must be further
investigated.
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